Literature DB >> 31120281

Effects of cannabinoid administration for pain: A meta-analysis and meta-regression.

Julio A Yanes1, Zach E McKinnell1, Meredith A Reid2, Jessica N Busler1, Jesse S Michel1, Melissa M Pangelinan3, Matthew T Sutherland4, Jarred W Younger5, Raul Gonzalez4, Jennifer L Robinson1.   

Abstract

Chronic pain states have resulted in an overreliance on opioid pain relievers, which can carry significant risks when used long term. As such, alternative pain treatments are increasingly desired. Although emerging research suggests that cannabinoids have therapeutic potential regarding pain, results from studies across pain populations have been inconsistent. To provide meta-analytic clarification regarding cannabis's impact on subjective pain, we identified studies that assessed drug-induced pain modulations under cannabinoid and corresponding placebo conditions. A literature search yielded 25 peer-reviewed records that underwent data extraction. Baseline and end-point data were used to compute standardized effect size estimates (Cohen's d) across cannabinoid administrations (k = 39) and placebo administrations (k = 26). Standardized effects were inverse-variance weighted and pooled across studies for meta-analytic comparison. Results revealed that cannabinoid administration produced a medium-to-large effect across included studies, Cohen's d = -0.58, 95% confidence interval (CI) [-0.74, -0.43], while placebo administration produced a small-to-medium effect, Cohen's d = -0.39, 95% CI [-0.52, -0.26]. Meta-regression revealed that cannabinoids, β = -0.43, 95% CI [-0.62, -0.24], p < .05, synthetic cannabinoids, β = -0.39, 95% CI [-0.65, -0.14], p < .05, and sample size, β = 0.01, 95% CI [0.00, 0.01], p < .05, were associated with marked pain reduction. These outcomes suggest that cannabinoid-based pharmacotherapies may serve as effective replacement/adjunctive options regarding pain, however, additional research is warranted. Additionally, given demonstrated neurocognitive side effects associated with some constituent cannabinoids (i.e., THC), subsequent work may consider developing novel therapeutic agents that capitalize on cannabis's analgesic properties without producing adverse effects. (PsycINFO Database Record (c) 2019 APA, all rights reserved).

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31120281      PMCID: PMC6663642          DOI: 10.1037/pha0000281

Source DB:  PubMed          Journal:  Exp Clin Psychopharmacol        ISSN: 1064-1297            Impact factor:   3.157


  80 in total

1.  Quantifying heterogeneity in a meta-analysis.

Authors:  Julian P T Higgins; Simon G Thompson
Journal:  Stat Med       Date:  2002-06-15       Impact factor: 2.373

Review 2.  Measuring inconsistency in meta-analyses.

Authors:  Julian P T Higgins; Simon G Thompson; Jonathan J Deeks; Douglas G Altman
Journal:  BMJ       Date:  2003-09-06

Review 3.  Sex differences in cannabinoid pharmacology: a reflection of differences in the endocannabinoid system?

Authors:  Rebecca M Craft; Julie A Marusich; Jenny L Wiley
Journal:  Life Sci       Date:  2012-06-20       Impact factor: 5.037

4.  Small studies are more heterogeneous than large ones: a meta-meta-analysis.

Authors:  Joanna IntHout; John P A Ioannidis; George F Borm; Jelle J Goeman
Journal:  J Clin Epidemiol       Date:  2015-04-02       Impact factor: 6.437

5.  The numeric rating scale for clinical pain measurement: a ratio measure?

Authors:  Craig T Hartrick; Juliann P Kovan; Sharon Shapiro
Journal:  Pain Pract       Date:  2003-12       Impact factor: 3.183

Review 6.  The induction of pain: an integrative review.

Authors:  M J Millan
Journal:  Prog Neurobiol       Date:  1999-01       Impact factor: 11.685

Review 7.  Cannabinoid-based medicines for neurological disorders--clinical evidence.

Authors:  Stephen Wright
Journal:  Mol Neurobiol       Date:  2007-06-29       Impact factor: 5.590

Review 8.  Effects of cannabis on neurocognitive functioning: recent advances, neurodevelopmental influences, and sex differences.

Authors:  Natania A Crane; Randi Melissa Schuster; Paolo Fusar-Poli; Raul Gonzalez
Journal:  Neuropsychol Rev       Date:  2012-11-06       Impact factor: 7.444

Review 9.  Pharmacological treatment of painful HIV-associated sensory neuropathy: a systematic review and meta-analysis of randomised controlled trials.

Authors:  Tudor J C Phillips; Catherine L Cherry; Sarah Cox; Sarah J Marshall; Andrew S C Rice
Journal:  PLoS One       Date:  2010-12-28       Impact factor: 3.240

10.  PSYCHOLOGY. Estimating the reproducibility of psychological science.

Authors: 
Journal:  Science       Date:  2015-08-28       Impact factor: 47.728

View more
  9 in total

Review 1.  Cannabinoids in the descending pain modulatory circuit: Role in inflammation.

Authors:  Courtney A Bouchet; Susan L Ingram
Journal:  Pharmacol Ther       Date:  2020-01-29       Impact factor: 12.310

2.  Using cannabis for pain management after spinal cord injury: a qualitative study.

Authors:  John A Bourke; Victoria J Catherwood; Joanne L Nunnerley; Rachelle A Martin; William M M Levack; Bronwyn L Thompson; Richard H Acland
Journal:  Spinal Cord Ser Cases       Date:  2019-10-08

3.  A Mapping Literature Review of Medical Cannabis Clinical Outcomes and Quality of Evidence in Approved Conditions in the USA from 2016 to 2019.

Authors:  Sebastian Jugl; Aimalohi Okpeku; Brianna Costales; Earl J Morris; Golnoosh Alipour-Haris; Juan M Hincapie-Castillo; Nichole E Stetten; Ruba Sajdeya; Shailina Keshwani; Verlin Joseph; Yahan Zhang; Yun Shen; Lauren Adkins; Almut G Winterstein; Amie Goodin
Journal:  Med Cannabis Cannabinoids       Date:  2021-02-25

Review 4.  Alternative pain management via endocannabinoids in the time of the opioid epidemic: Peripheral neuromodulation and pharmacological interventions.

Authors:  Ming Tatt Lee; Ken Mackie; Lih-Chu Chiou
Journal:  Br J Pharmacol       Date:  2021-12-07       Impact factor: 9.473

5.  Opioid Use in Patients With Cervical Cancer at Two Urban Medical Centers.

Authors:  Ritu Arya; Daniel Hong; Olivia Schultz; Jessica M Jutzy; Katherine Cotangco; Pamela Peters; Ellen W Daily; Anne R McCall; Andrew R Howard; Yasmin Hasan; Rajul Kothari; Christina H Son
Journal:  Adv Radiat Oncol       Date:  2021-10-20

6.  Study protocol for a phase II, double-blind, randomised controlled trial of cannabidiol (CBD) compared with placebo for reduction of brain neuroinflammation in adults with chronic low back pain.

Authors:  Chelsea K Pike; Minhae Kim; Kristina Schnitzer; Nathaniel Mercaldo; Robert Edwards; Vitaly Napadow; Yi Zhang; Erin Janas Morrissey; Zeynab Alshelh; A Eden Evins; Marco L Loggia; Jodi M Gilman
Journal:  BMJ Open       Date:  2022-09-19       Impact factor: 3.006

7.  Promising Health Benefits of Adjuvant Acmella and Zingiber Extracts Combined with Coenzyme Q10 Phytosomes, Supplementation in Chronic Pain Treated with Medical Cannabis: A Prospective and Open-Label Clinical Study.

Authors:  Paolo Poli; Simona Carnevale; Antonella Scocca; Pier Luigi Davolio; Simona Busi; Martino Meneghin; Giovanna Petrangolini; Antonella Riva
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-13       Impact factor: 2.650

8.  Pilot clinical and pharmacokinetic study of Δ9-Tetrahydrocannabinol (THC)/Cannabidiol (CBD) nanoparticle oro-buccal spray in patients with advanced cancer experiencing uncontrolled pain.

Authors:  Stephen Clarke; Belinda E Butcher; Andrew J McLachlan; Jeremy D Henson; David Rutolo; Sean Hall; Luis Vitetta
Journal:  PLoS One       Date:  2022-10-14       Impact factor: 3.752

Review 9.  Understanding the Medical Chemistry of the Cannabis Plant is Critical to Guiding Real World Clinical Evidence.

Authors:  Karim S Ladha; Prabjit Ajrawat; Yi Yang; Hance Clarke
Journal:  Molecules       Date:  2020-09-04       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.